Hope Springs as New Alzheimer’s Medication Reaches Trial Stage
Medical experts are “cautiously optimistic” as a promising experimental drug aimed to slow down the progression of Alzheimer’s disease has reached its trial stage and is showing improved cognition and reduced clinical signs among those who participated in the study.
"These were people with very mild impairments, some confusion, forgetting someone's name on occasion. That's the goal: to stop Alzheimer's disease when it's in the mildest presentation," said Dr. Lynn Kramer, the chief clinical and medical officer for Eisai in a CNN report.
The same report stated that the an anti-amyloid antibody medication, dubbed as BAN2401, has “not only reduced the formulation of new beta amyloid clusters in the brain, it reduced existing clusters by 70% on average.”
Kramer, in a Washington Post re...
